CPI-1205 is under clinical development by MorphoSys and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase I drugs for Marginal Zone B-cell Lymphoma have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CPI-1205’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CPI-1205 is under development for the treatment of metastatic castration-resistant prostate cancer and B-Cell lymphomas including follicular lymphoma, diffuse large B cell lymphoma and marginal zone lymphomas. The drug candidate is administered orally. It belongs to pyridone family and targets the EZH2 (histone methyltransferase (HMT) subunit of the Polycomb Repressor complex 2 (PRC2)). It was also under development for metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, metastatic transitional (urothelial) tract cancer, multiple myeloma.
MorphoSys is commercial-stage biopharmaceutical company that develop monoclonal antibodies for therapeutic and research applications, with focused on the treatment of cancer and autoimmune diseases. The company’s product pipeline includes tafasitamab, pelabresib, cpi-0209, gantenerumab, otilimab, ianalumab, abelacimab, felzartamab, setrusumab, NOV-8, NOV-14 and MOR210. Its Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. The company provides clinical trials for cancer and inflammatory disorders. MorphoSys also conducts research and development activities with pharmaceutical and biotechnology companies. The company owns a regional licensing agreement to develop and commercialize products. It operates in the US. MorphoSys is headquartered in Planegg, Bayern, Germany.
For a complete picture of CPI-1205’s drug-specific PTSR and LoA scores, buy the report here.